Type 2 diabetes mellitus and kidney disease are interlinked, with the coexistence of these conditions complicating therapeutic decisions, especially concerning antidiabetic agents. This review critically examines the efficacy and safety profiles of sitagliptin and dapagliflozin in managing T2DM in patients with renal impairment. Drawing from clinical trials and population studies, dapagliflozin appears superior in reducing cardiovascular and renal outcomes but poses a higher risk of genital infections, while sitagliptin shows favorable glycemic control with minimal risk of hypoglycemia but may be associated with a higher risk of acute kidney injury. Additional focus is placed on drug mechanisms, dosing adjustments, and their applicability in different stages of renal dysfunction. Dapagliflozin has demonstrated strong renal and cardiovascular protective effects, making it a preferred option in patients at high risk of complications, whereas sitagliptin remains a valuable alternative in elderly patients or those with mild renal impairment due to its better safety and tolerability. Both agents need to be considered individually as per renal status, comorbidity, and patient-related issues. Highlighting a personalized, evidence-based approach, this review outlines the clinical relevance of these therapies and their broader implications for managing diabetic kidney disease.